KLP Kapitalforvaltning AS acquired a new stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,500 shares of the biopharmaceutical company's stock, valued at approximately $1,712,000.
Several other institutional investors and hedge funds have also recently made changes to their positions in ITCI. China Universal Asset Management Co. Ltd. raised its holdings in Intra-Cellular Therapies by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company's stock valued at $1,878,000 after buying an additional 2,157 shares during the last quarter. Barclays PLC raised its stake in shares of Intra-Cellular Therapies by 282.0% during the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company's stock valued at $2,521,000 after acquiring an additional 25,435 shares during the last quarter. Oak Ridge Investments LLC boosted its holdings in shares of Intra-Cellular Therapies by 74.1% during the fourth quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company's stock worth $1,656,000 after purchasing an additional 8,440 shares during the period. Principal Financial Group Inc. grew its stake in shares of Intra-Cellular Therapies by 3.3% in the third quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company's stock worth $43,735,000 after purchasing an additional 18,865 shares during the last quarter. Finally, Merit Financial Group LLC purchased a new position in Intra-Cellular Therapies during the 4th quarter valued at about $206,000. Institutional investors own 92.33% of the company's stock.
Intra-Cellular Therapies Trading Up 0.1 %
NASDAQ:ITCI traded up $0.11 during trading hours on Monday, reaching $131.92. 2,957,650 shares of the company traded hands, compared to its average volume of 1,397,765. The business's 50-day moving average price is $129.12 and its two-hundred day moving average price is $99.80. Intra-Cellular Therapies, Inc. has a 1 year low of $64.09 and a 1 year high of $131.95. The stock has a market capitalization of $14.05 billion, a P/E ratio of -151.63 and a beta of 0.69.
Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $199.22 million during the quarter, compared to analysts' expectations of $205.08 million. As a group, equities analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of brokerages have recently weighed in on ITCI. Leerink Partnrs lowered Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Piper Sandler restated a "neutral" rating and issued a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, January 14th. Finally, Mizuho cut shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and reduced their price target for the company from $140.00 to $132.00 in a research report on Monday, February 24th. Ten equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $106.08.
Get Our Latest Analysis on Intra-Cellular Therapies
About Intra-Cellular Therapies
(
Free Report)
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Further Reading
Before you consider Intra-Cellular Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.
While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
